GIP, GLP-1 and glucagon pathways

Retatrutide

Investigational; human clinical trials are ongoing

UNDERSTAND IT SIMPLY

What is Retatrutide?

Retatrutide is an experimental molecule that acts on three signaling systems: GIP, GLP-1 and glucagon. GIP and GLP-1 help the body respond to food. Glucagon is involved in how the body manages stored energy. Researchers want to understand what happens when all three pathways are activated by one molecule.

Human trials are examining body weight, blood-sugar measurements, liver-related markers and other metabolic outcomes. Early results are not the same as a final conclusion. Larger studies, longer follow-up and careful safety monitoring are still needed. Retatrutide remains investigational, and this page provides no access, dosing, preparation or personal-use guidance.

WHAT RESEARCHERS EXAMINE

Body-weight and metabolic endpoints

Glycemic measurements

Cardiovascular, liver and kidney questions

HUMAN EVIDENCE

What human research has reported.

Promising human findings, but retatrutide remains investigational.

Phase 2 trial groups had substantial average weight reduction; some also improved blood-sugar and liver-fat measurements.

These are group-level study observations—not promises, instructions or personal predictions. Benefits, side effects, study design and uncertainty must be considered together.

GO TO THE SOURCE

Read beyond the summary.

ClinicalTrials.gov studies↗PubMed research↗

INFORMATION—NOT A PRODUCT PAGE.

PJ Peptides does not offer this compound for sale. This page does not provide medical advice, diagnosis, treatment, dosing, preparation, administration or sourcing guidance.